Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-associated nephropathy

J Winston1, P E Klotman

  • 1Mount Sinai School of Medicine, New York, NY 10029, USA.

The Mount Sinai Journal of Medicine, New York
|February 12, 1998
PubMed
Summary
This summary is machine-generated.

HIV-associated nephropathy (HIVAN) is a common cause of kidney disease in HIV-1 patients. Further research is needed to understand its cause and explore antiviral therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposures in early life: associations with DNA promoter methylation in breast tumors.

Journal of developmental origins of health and disease·2014
Same author

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study.

Current Alzheimer research·2013
Same author

Malteser compromise.

British dental journal·2012
Same author

PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity.

Neurogastroenterology and motility·2010
Same author

Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours.

Veterinary and comparative oncology·2009
Same author

Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.

HIV medicine·2006
Same journal

Farewell message from Penny A. Asbell, MD, FACS, MBA, Editor-in-Chief of the Mount Sinai Journal of Medicine.

The Mount Sinai journal of medicine, New York·2012
Same journal

Minority undergraduate programs intended to increase participation in biomedical careers.

The Mount Sinai journal of medicine, New York·2012
Same journal

Future of electronic health records: implications for decision support.

The Mount Sinai journal of medicine, New York·2012
Same journal

AA amyloidosis: Mount Sinai experience, 1997-2012.

The Mount Sinai journal of medicine, New York·2012
Same journal

Amyloid neuropathies.

The Mount Sinai journal of medicine, New York·2012
Same journal

Should your family history of coronary heart disease scare you?

The Mount Sinai journal of medicine, New York·2012
See all related articles

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Virology

Background:

  • HIV-1 infection poses significant risk for diverse renal diseases.
  • HIV-associated nephropathy (HIVAN) is the primary cause of chronic renal insufficiency in HIV-1+ individuals.
  • Morphologic hallmarks of HIVAN include enlarged kidneys and focal glomerulosclerosis.

Purpose of the Study:

  • To discuss the pathogenesis, epidemiology, and treatment of HIVAN.
  • To review renal disease databases for epidemiological insights.
  • To present institutional experience with HIVAN.

Main Methods:

  • Review of United States Renal Data Systems and New York State End Stage Renal Disease Network databases.
  • Analysis of institutional data from Mount Sinai Medical Center.

Related Experiment Videos

  • Literature review on HIVAN pathogenesis and treatment.

    • Main Results:

    • The precise etiology of HIVAN remains undetermined, though viral protein or gene expression is implicated.
    • HIVAN is the fourth leading cause of end-stage renal disease (ESRD) in Black adults (20-64 years).
    • At Mount Sinai Hospital, HIVAN represents 20% of new ESRD cases in young Black adults, making it the third leading cause.

    Conclusions:

    • Renal biopsies are crucial for diagnosing renal disease in HIV-1+ patients and assessing HIVAN incidence.
    • Understanding the underlying causes of HIVAN requires focused investigation.
    • Initiating a multicenter trial for antiviral therapy in HIVAN is recommended.